clinical features including histology, block 2: laboratory and treatment factors, block 3: demographic and traditional risk factors). Variables included in the final multivariate model were selected on the following basis: P-value <0.1 in univariate or block regression or otherwise deemed clinically significant.

Results: 881 patients were included of which 626 (71.1%) were females. Mean age was 73 years (SD 9), 490 patients (55.6%) died during the study period (1 January 1972 – 31 December 2012). Characteristics and mortality for the GCA-cohort compared to matched controls have been published previously [3]. Within the GCA-cohort we found that presenting with visual disturbance (any) or scalp necrosis was associated with increased risk of death in univariate analysis (Figure 1). However, in multivariate analysis the traditional risk factors (age, smoking, hypertension and previous cardiovascular disease) were more strongly associated with risk of death. Among laboratory parameters only Hemoglobin (Hb) levels were significantly associated with risk of death with increasing Hb-levels indicating decreased risk. Neither temporal artery biopsy result nor initial or maximal (before first tapering) Prednisolone dose were found to be associated with risk of death. Results from univariate and the final multivariate models are presented in Figure 1.

Figure 1.

Conclusion: In our large cohort of GCA-patients the risk of death was found to be predominantly predicted by age (HR 2.81) and traditional risk factors (smoking (HR 1.61), hypertension (HR 1.48) and previous cardiovascular disease (HR 1.26)). Visual disturbance (HR 1.40), visual loss in particular (HR 2.37), and scalp necrosis (HR 3.42) were found to be the clinical features most associated with risk of death. However, we note that our material lacked information about extra-cranial (large vessel) vasculitis, which may also carry increased risk of death.

REFERENCES:

Disclosure of Interests: Lene Kristin Brekke Grant/research support from: unrestricted research grant from MSJ, Bjørn Tilde Svene Fveng Consultant of: Been part of advisory board for Lilly, Jørg Assmus: None declared.

DOI: 10.1136/annrheumdis-2021-eular.1988

POS0340

VASULAR IMAGING IN PATIENTS WITH REFRACOARY TAKAYASU ARTERITIS TREATED WITH TOCILIZUMB: ANALYSIS FROM A RANDOMIZED CONTROLLED TRIAL


1National Cerebral and Cardiovascular Center Research Institute, Department of Vascular Physiology, Suita, Japan; 2Osaka University Graduate School of Medicine, Department of Cardiovascular Medicine, Osaka, Japan; 3Osaka University Graduate School of Medicine, Department of Future Diagnostic Radiology, Osaka, Japan; 4Chugui University Graduate School of Medicine, Department of Diagnostic Radiology, Osaka, Japan; 5Chugui Pharmaceutical Co., Ltd., Medical Science Department, Medical Affairs Division, Tokyo, Japan; 6Chugui Pharmaceutical Co., Ltd., Biometrics Department, Clinical Development Division, Tokyo, Japan; 7Chugui Pharmaceutical Co., Ltd., Primary Clinical Development, Clinical Development Division, Tokyo, Japan; 8Nippon Medical School, Department of Radiology, Tokyo, Japan; 9University of Cambridge, Department of Medicine, Cambridge, United Kingdom

Background: In the TAKT study, a randomized controlled trial of tocilizumab (TCZ) in patients with refractory Takayasu arteritis (TAK) in Japan, the primary end point of time to relapse after induction of remission with glucocorticoid (GC) treatment showed a trend favoring TCZ over placebo (hazard ratio 0.41 [95.41% confidence interval, 0.15–1.10; p=0.0598]), but the double-blind period was too short for imaging evaluation.

Objectives: To independently evaluate vascular imaging in a post hoc analysis of radiographs from the TAKT study.

Methods: Computed tomography images from patients in the TAKT study were evaluated by three independent radiologists who were not involved in the original trial. Patients who received TCZ and had computed tomography images available (n=28) were included. Assessments were made in 22 arteries for the change from baseline in wall thickness (primary end point), dilatation/aneurysm, stenosis/occlusion, or wall enhancement for at least 96 weeks after the start of tocilizumab treatment. Patient-level assessments were also conducted.

Results: Among 28 patients who received at least one dose of TCZ and for whom images were available, 86.7% of 22 arteries had improved/stable (no progression) wall thickness at week 96. The proportions of patients with no progression, partially progressed, or newly progressed lesions were 57.1%, 10.7%, and 28.6% for wall thickness, and the proportions without progressed lesions were 92.9% for dilatation/aneurysm and 85.7% for stenosis/occlusion (Figure 1). Patients with newly progressed lesions, reflecting more refractory disease, were receiving glucocorticoid doses that could not be reduced below 0.1 mg/kg/day at week 96.

Conclusion: Approximately 60% of patients with TAK treated with tocilizumab did not experience progression in wall thickness. Few patients experienced progressive dilatation/aneurysm or stenosis/occlusion. Wall thickness progression likely resulted from refractory TAK. Patients who experience this should be monitored regularly by imaging, and additional glucocorticoid or immunosuppressives treatment should be considered to avoid vascular progression.

REFERENCES:

Figure. Evaluation of arteries per patient (n=28).


DOI: 10.1136/annrheumdis-2021-eular.2768

POS0341

SVCAM-1 EXPRESSION IN TAKAYASU ARTERITIS TREATED WITH TOCILIZUMB: A PROSPECTIVE PILOT STUDY

S. Ackermann1, P. Villegier2, A. Gloor3, K. E. Eriksson4, M. Seidel4. 1Hospital Biel, Rheumatology, Biel, Switzerland; 2Insepitalp, Rheumatology, Bern, Switzerland; 3Stanford University, Immunology and Rheumatology, Stanford, United States of America

Background: Takayasu arteritis (TA) is a rare disease, its diagnosis is often delayed by years. Biomarkers might be helpful for earlier diagnosis and for monitoring treatment. We have described serum soluble vascular cell adhesion molecule-1 (sVCAM-1) as a marker of inflammation in a variety of rheumatic diseases, including vasculitis (1). Tocilizumab (TCZ) is a monoclonal antibody against the interleukin-6 receptor with established benefits in TA (2). It may spare against the interleukin-6 receptor with established benefits in TA (2). It may spare


DOI: 10.1136/annrheumdis-2021-eular.2768
null